革命医药

最新新闻

• BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $264
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $255
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Morgan Stanley Initiates Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $255
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $251
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $230
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Fortrea Holdings Inc. (FTRE)
  TipRanks · 2026/9/3
• Guggenheim Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $275
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Jefferies Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $270
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $246
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $230
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $275
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/9/15
• 评级变动
  BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $265
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $315
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $265
  \u5e02\u573a\u8d44\u8baf · 2026/8/29
• Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $240
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $259 to $264
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Goldman Sachs Initiates Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $267
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Brookline Capital Initiates Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $318
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $225 to $320
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  TD Cowen Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $205.15
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $315
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $239 to $320
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• 评级变动
  Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $231
  \u5e02\u573a\u8d44\u8baf · 2026/8/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。